Loading companies…
S
Senticell
United States · Biotech
Senticell is developing a liquid-biopsy diagnostic based on nucleic acids associated with red blood cells.
Product and customers
Its blood-sample platform analyzes RBC-bound and circulating DNA, RNA, and protein biomarkers to detect disease signals that plasma-only testing may miss, with initial focus on cancer. The company is advancing clinical validation through prospective oncology studies with Penn Medicine; it remains a developing diagnostics platform.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Seed | $7M | Capital Factory — ParticipantEvoce Capital — ParticipantScalpel Ventures — ParticipantThe Venture City — Participant |
Investors
Capital FactoryJoined SeedEvoce CapitalJoined SeedScalpel VenturesJoined SeedThe Venture CityJoined SeedCoverage
Sep 1, 2026Senticell · SeedSimilar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
ATAptadir TherapeuticsRNA therapeutics designed to restore expression of silenced genes€40M · Seed